Objective:
Evaluate the market potential of the newly acquired asset to determine its long-term value and strategic fit within the company&rsquo;s portfolio.
Problem Statement
A leading global pharmaceutical company acquired a mid-cap biotech firm with a promising oncology asset. The newly acquired drug, a novel class of therapy, demonstrated significant potential in targeting multiple tumor types, particularly in combination with the company&rsquo;s in-house <a href="https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market-insights">immune checkpoint inhibitor</a> (CPI).
Given the substantial investment required for late-stage development and commercialization, the company sought a comprehensive evaluation of the asset&rsquo;s market value. The assessment aimed to inform a strategic decision:
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal">Should the company retain and invest in the asset for long-term development?</li>
<li class="MsoNormal">Or should it divest the product to <a href="https://www.delveinsight.com/consulting/pharmaceutical-portfolio-management-solutions">optimize its portfolio</a> and allocate resources more effectively?</li>
</ul>
To guide this critical decision, a robust <a href="https://www.delveinsight.com/consulting/market-assessment-services">market evaluation</a> was conducted, assessing competitive positioning, clinical differentiation, and financial viability.
Our Approach &amp; Methodology
We employed a multi-faceted approach, leveraging both <a href="https://www.delveinsight.com/consulting/primary-research-services">primary research</a> and secondary research methodologies to provide a data-driven market assessment. Our key focus areas included:
1. Extensive Secondary Research
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal">Analyzed published clinical data, regulatory filings, and scientific literature to understand the asset&rsquo;s therapeutic positioning.</li>
<li class="MsoNormal">Assessed historical market trends and emerging treatment paradigms within the relevant oncology indications.</li>
</ul>
2. <a href="https://www.delveinsight.com/consulting/primary-research-services">Extensive Primary Research</a>
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal">Engaged with key stakeholders, including oncologists, researchers, and payers, to gauge perceptions of the asset&rsquo;s clinical and commercial potential.</li>
<li class="MsoNormal">Gathered real-world insights on prescribing behaviors, treatment preferences, and unmet needs.</li>
</ul>
3. <a href="https://www.delveinsight.com/consulting/competitive-intelligence-services">Competitive Benchmarking</a>
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal">Identified and evaluated competing therapies (both marketed and pipeline) to determine how the acquired asset compares in terms of efficacy, safety, and market traction.</li>
<li class="MsoNormal">Assessed competitor pricing strategies, reimbursement dynamics, and commercial success.</li>
</ul>
4. <a href="https://www.delveinsight.com/consulting/pipeline-assessment-services">Clinical Trials Analysis</a>
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal">Evaluated ongoing and completed clinical trials for the asset, comparing study designs, endpoints, and trial outcomes with competing therapies.</li>
<li class="MsoNormal">Assessed the likelihood of <a href="https://www.delveinsight.com/consulting/regulatory-analysis-services">regulatory approval</a> based on current clinical data.</li>
</ul>
5. Strategic Insights on Companies
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal">Studied key players active in the relevant oncology indications, <a href="https://www.delveinsight.com/consulting/partner-identification-services">identifying potential partners</a>, <a href="https://www.delveinsight.com/consulting/licensing-services">licensing opportunities</a>, and acquisition trends.</li>
<li class="MsoNormal">Assessed the positioning and growth strategies of direct and indirect competitors.</li>
</ul>
6. Market Forecasting
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal">Conducted quantitative modeling to estimate market size, revenue potential, and growth trajectories.</li>
<li class="MsoNormal">Assessed the impact of regulatory changes, pricing strategies, and competitive landscape shifts on long-term market sustainability.</li>
</ul>
Results &amp; Key Insights
Our comprehensive evaluation provided the pharmaceutical company with:
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal">Executive-Level Analysis: A high-level assessment of the asset&rsquo;s market viability and strategic fit.</li>
<li class="MsoNormal">Therapy Area &amp; Disease Landscape: In-depth analysis of the indications, including epidemiology, current treatment options, and unmet needs.</li>
<li class="MsoNormal">Treatment Algorithm Insights: Understanding how the asset would fit within standard-of-care pathways.</li>
<li class="MsoNormal">Market Drivers &amp; Barriers: Identification of factors influencing adoption, pricing, and reimbursement potential.</li>
<li class="MsoNormal">SWOT Analysis: Strengths, weaknesses, opportunities, and threats associated with the asset.</li>
<li class="MsoNormal">Competitive Landscape Overview: Evaluation of marketed and pipeline products to understand the asset&rsquo;s positioning.</li>
<li class="MsoNormal">Competitor Attribute Analysis: Detailed comparison of key competing therapies, highlighting differentiation points.</li>
<li class="MsoNormal">Market Size Estimation: Forecasting market potential in terms of value and volume, covering both marketed and upcoming products.</li>
<li class="MsoNormal">Revenue Forecasting &amp; Strategic Recommendations:</li>
<ul style="margin-top: 0cm;" type="circle">
<li class="MsoNormal">Projected financial performance of the acquired asset under different scenarios.</li>
<li class="MsoNormal">Our final recommendation on whether the company should&nbsp;continue investing in development&nbsp;or&nbsp;pursue divestment&nbsp;for maximum value realization.</li>
</ul>
</ul>
Conclusion
The evaluation enabled the company to make a well-informed strategic decision regarding the acquired oncology asset. By combining deep market insights, <a href="https://www.delveinsight.com/consulting/competitive-intelligence-services">competitive intelligence</a>, and financial forecasting, we provided a clear roadmap for maximizing the asset&rsquo;s value&mdash;whether through continued development, partnerships, or divestment

A global pharmaceutical company wished to evaluate the market value of an asset obtained by acquiring a mid-cap company. The new class of drug showed the potential in targeting multiple tumors in combination with their in-house immune checkpoint inhibitor (CPI). The assessment formed the basis of their decision.

Market Assessment

Immune Checkpoint Inhibitor market assessment provides insights into the marketed and pipeline products, unmet needs, competitors, and market dynamics